New Breast Cancer-fighting drug: Palbociclib by Pfizer

Pharma giant Pfizer is looking forward to a new year in R&D, and hopefully a new drug approval with Palbociclib, (Ibrance) which is touted as having mega-blockbuster potential. Palbociclib is a CDK4/6 inhibitor for breast cancer, most likely for use with letrozole, and received FDA priority review designation in October 2014. It also received breakthrough drug status. Pfizer's seeking approval in treatment naive postmenopausal women with metastatic ER+, HER2-breast cancer. Analysts forecast sales at roughly $3 billion a year by 2020 if approved. FDA is expected to make a decision by April 13, 2015. Lilly and Novartis have CDK inhibitors in the works, too.